Register now to R3i !
Your Login
Your Password
Confirm Password  
Your Email
R3i EVENTS
26 august 2017, Barcelona, Spain
ESC 2017: New approaches to targeting residual cardiovascular risk
Read full report..
R3i editorial
4 December 2017

Prof. Jean Charles Fruchart, Prof. Michel Hermans, Prof. Pierre Amarenco
Residual risk of heart failure: how to address this global epidemic?Read more...

Heart failure affects more than 26 million people worldwide, and poses a huge economic burden to society. In 2012, the annual costs of heart failure management were estimated at $108 billion, although this is likely to be an underestimate of the true burden due to an aging, rapidly expanding and industrializing global population.
This cost is largely driven by the need for repeated hospitalization. Indeed, a recent US analysis illustrates this; about one in five patients was readmitted within 30 days of the index hospitalization, one in three readmitted within 60 days, and nearly half readmitted within 90 days , higher than that for other cardiovascular complications including acute myocardial infarction (AMI) and coronary artery bypass surgery...
landmark study
4 December 2017

New analysis from Copenhagen General Population Study reaffirms the importance of elevated remnant cholesterol as a risk factor for MIRead more...

Evidence from both observational and genetic studuies have demonstrated that remnant cholesterol (for which triglycerides are a marker) is a causal risk factor for ischaemic heart disease.(1-3) The atherogenicity of remnant cholesterol is explained by retention of the remnants of chylomicrons and large very low-density...
focus on...
4 December 2017

Nonfasting triglycerides and heart failure riskRead more...

Globally, heart failure poses an increasing burden with repeated hospitalization a key driver of cost. While statins reduce the risk of myocardial infarction (MI) in patients with and without pre-existing heart disease, and therefore in theory should have a beneficial effect on the development of...
R3i Activities Highlights
10 -12 june 2017, St Petersburg, Russia
MSDA 2017 - 12th Metabolic Syndrome, type II Diabetes and Atherosclerosis Congress
Read full report..
recent publication

Obesity, genetic risk and triglyceridesRead more...

The current study corroborates previous findings that obesity accentuates the effects of common genetic susceptibility variants that regulate levels of...
recent publication

Obesity a key driver of the diabetes burden in China. Read more...

Type 2 diabetes prevalence in China has escalated by more than 10-fold over the last 30 years, with recent estimates...
recent publication

New review of pemafibrate, novel SPPARMalpha Read more...

Selective peroxisome proliferator-activated receptor alpha modulators (SPPARM?) may offer a novel therapeutic approach to the management of atherogenic dyslipidaemia. The...
recent publication

Missense APOC3 variant lowers plasma triglyceridesRead more...

APOC3 encodes apolipoprotein (apo) C-III, a critical inhibitor of triglyceride lipolysis and remnant triglyceride rich lipoprotein clearance. Genetic studies have...
recent publication

Lipid lowering therapy in patients with atherosclerotic cardiovascular diseases: What matters in the real world?Read more...

This multicenter registry cohort study in Taiwan shows that failure to achieve recommended low-density lipoprotein cholesterol (LDL-C) goal, rather than...
recent publication

Impaired HDL anti-inflammatory activity in diabetesRead more...

Increasingly it is thought that the functionality of high-density lipoprotein (HDL) may have a pathophysiologically important impact in delaying the...
PCSK9 and Atherosclerosis
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professors Jean Davignon (Vice-President of the R3i foundation), Jean-Charles Fruchart (President of R3i) and Michel Hermans (R3i General Secretary), the latest downloadable deck of 242 slides discusses the potential role for anti-PCSK9 mAbs in the future management of cardiovascular disease.
SSPARMa at the Crossroads of Obesity, Diabetes and Cardiovascular Diseases
Downloadable slidekit
PCSK9 downloadable slidekit
Created by Professor Jean-Charles Fruchart, President of the R3i foundation, this downloadable library of 238 slides discusses the rationale and therapeutic opportunities for SPPARĪ±Ms in the future management of cardiovascular diseases.

What is residual risk ?

Residual risk of vascular events persisting in patients at treatment goals according to current standards of care or failing to meet goals, including risk related to dyslipidemia, high blood pressure, hyperglycemia, systemic inflammation and unhealthy lifestyles.

What is the Initiative ?

The R3i, a worldwide, academic, multidisciplinary non-profit organization, aims to successfully address the excessively high risk of macro- and micro-vascular complications in patients with atherogenic dyslipidemia, characterised by elevated triglycerides and low levels of high-density lipoprotein (HDL) cholesterol and unaddressed by current standards of care.